Comparison of particle-size analyzing laboratory methods [PDF]
, 2015 Patients with chronic renal failure are known to have renal osteodystrophy (bone disease) and increased calcification of vessels. A new marker of bone disease, sclerostin, the two pro-inflammatory cytokines tumour necrosis factor-alpha (TNF-alpha) and ...
Barta, Károly +6 more
core +1 more source
Glucocorticoids dexamethasone and prednisolone suppress fibroblast growth factor 23 (FGF23)
Journal of molecular medicine, 2021 Fibroblast growth factor 23 (FGF23) is a hormone mainly secreted by bone cells. Its most prominent effects are the regulation of renal phosphate reabsorption and calcitriol (active vitamin D, 1,25(OH)2D3) formation, effects dependent on its co-receptor ...
M. Feger +7 more
semanticscholar +1 more source
International Journal of Molecular Sciences, 2020 The bone-derived hormone fibroblast growth factor 23 (FGF23) acts in concert with parathyroid hormone (PTH) and the active vitamin D metabolite calcitriol in the regulation of calcium (Ca) and phosphate (P) homeostasis.
M. Mace, K. O̸lgaard, E. Lewin
semanticscholar +1 more source
Fibroblast growth factor 23 and cardiovascular disease in patients with chronic kidney disease [PDF]
, 2018 Chronic kidney disease (CKD) has been known to be associated with an increased risk of cardiovascular (CV) mortality and morbidity in Japan. Although traditional risk factors contribute to the development of CV disease in CKD patients, they cannot fully ...
NITTA Kosaku
core +2 more sources
ESC Heart Failure, 2020 Besides regulating calcium‐phosphate metabolism, fibroblast growth factor 23 (FGF‐23) has been associated with incident heart failure (HF) and left ventricular hypertrophy.
C. Roy +16 more
semanticscholar +1 more source
A rare cause of atraumatic fractures: case series of four patients with tumor-induced osteomalacia
Clinical Diabetes and Endocrinology, 2020 Background Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome that presents with hypophosphatemia, bone pain, muscle weakness and fractures.
Debbie W. Chen +4 more
doaj +1 more source
Serum fibroblast growth factor 23, serum iron and bone mineral density in premenopausal women [PDF]
, 2016 Fibroblast growth factor 23 (FGF23) circulates as active protein and inactive fragments. Low iron status increases FGF23 gene expression, and iron deficiency is common. We hypothesized that in healthy premenopausal women, serum iron influences C-terminal
Acton, Anthony +7 more
core +1 more source
Gla-rich protein (GRP) as an early and novel marker of vascular calcification and kidney dysfunction in diabetic patients with CKD: a pilot cross-sectional study [PDF]
, 2020 Vascular calcification (VC) is one of the strongest predictors of cardiovascular risk in chronic kidney disease (CKD) patients. New diagnostic/prognostic tools are required for early detection of VC allowing interventional strategies.
Almeida, Edgar de +12 more
core +1 more source
Fibroblast-growth factor 23 promotes terminal differentiation of ATDC5 cells. [PDF]
PLoS ONE, 2017 Fibroblast Growth Factor 23 (FGF23) is well documented as a crucial player in the systemic regulation of phosphate homeostasis. Moreover, loss-of-function experiments have revealed that FGF23 also has a phosphate-independent and local impact on ...
Mathilde Guibert +3 more
doaj +1 more source
Inflammation regulates fibroblast growth factor 23 production [PDF]
Current Opinion in Nephrology and Hypertension, 2016 Fibroblast growth factor 23 (FGF23) is a hormone secreted by osteocytes and osteoblasts that regulates phosphorus and vitamin D homeostasis. FGF23 levels increase progressively in chronic kidney disease (CKD), and FGF23 excess might be a causal factor of left ventricular hypertrophy, CKD progression and death.
Connor, Francis, Valentin, David
openaire +2 more sources